| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Dermatology [D. B. E. E. M., D. S., S. I., Z. A. A.] and Environmental Health [K. D.], University of Cincinnati, Cincinnati, Ohio 45267-0592; Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Houston, TX [D. M.]; and Shriners Burns Institute, Cincinnati, Ohio [G. B.]
Melanin is thought to serve in photoprotection. To investigate this, we have compared the responses of cultured human melanocytes derived from different pigmentary phenotypes (skin types IVI) to a single irradiation with different doses of UVB light, ranging between 11.7 and 70.1 mJ/cm2. After UVB irradiation, heavily pigmented melanocytes had the same percent survival but a greater capacity to resume proliferation than their lightly pigmented counterparts. A significant increase in melanin content was observed in heavily pigmented but not in lightly pigmented melanocytes. Irradiation with UVB light blocked melanocytes, regardless of their melanin content, in G1, and induced the expression of the tumor suppressor p53 protein within 4 h. This induction steadily increased up to 48 h in lightly pigmented melanocytes; however, in heavily pigmented melanocytes, p53 level peaked at 24 h after UVB treatment and declined thereafter. Additionally, DNA from lightly pigmented melanocytes contained significantly higher numbers of cyclobutane pyrimidine dimers than did DNA from heavily pigmented melanocytes after irradiation with increasing doses of UVB light. We speculate that the prolonged induction of p53 in lightly pigmented melanocytes arrests them in G1 for a long time period in order to repair extensive DNA damage. The above described differences might partially explain the increased susceptibility of individuals with lightly pigmented skin compared to individuals with dark skin to the photodamaging and photocarcinogenic effects of sun exposure.
1 Supported in part by a grant from the Ohio Cancer Research Associates; National Institute of Environmental Health Sciences Grants 1 R01 ES06882-01A1 (Z.A.M.) and 5P30 ES06096-02; Shiseido Co., Ltd. (Z.A.M.); and NIH National Institute on Aging Grant AG00594-02 (E.E.M.).
2 Present address: Baylor College of Medicine, Huffington Center on Aging, One Baylor Plaza, Houston, TX.
3 To whom requests for reprints should be addressed, at Department of Immunology, University of Cincinnati, P.O. Box 670592, Cincinnati, OH 45267-0592.
Received 3/15/95. Accepted 7/19/95.
This article has been cited by other articles:
![]() |
Z. A. Abdel-Malek, A. L. Kadekaro, R. J. Kavanagh, A. Todorovic, L. N. Koikov, J. C. McNulty, P. J. Jackson, G. L. Millhauser, S. Schwemberger, G. Babcock, et al. Melanoma prevention strategy based on using tetrapeptide {alpha}-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity FASEB J, July 1, 2006; 20(9): 1561 - 1563. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Kadekaro, R. Kavanagh, H. Kanto, S. Terzieva, J. Hauser, N. Kobayashi, S. Schwemberger, J. Cornelius, G. Babcock, H. G. Shertzer, et al. {alpha}-Melanocortin and Endothelin-1 Activate Antiapoptotic Pathways and Reduce DNA Damage in Human Melanocytes Cancer Res., May 15, 2005; 65(10): 4292 - 4299. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bohm, I. Wolff, T. E. Scholzen, S. J. Robinson, E. Healy, T. A. Luger, T. Schwarz, and A. Schwarz {alpha}-Melanocyte-stimulating Hormone Protects from Ultraviolet Radiation-induced Apoptosis and DNA Damage J. Biol. Chem., February 18, 2005; 280(7): 5795 - 5802. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Scott, K. Wakamatsu, S. Ito, A. L. Kadekaro, N. Kobayashi, J. Groden, R. Kavanagh, T. Takakuwa, V. Virador, V. J. Hearing, et al. Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation J. Cell Sci., January 6, 2002; 115(11): 2349 - 2355. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Autier, R. Pedeux, and J.-F. Dore RESPONSE: Re: Sunscreen Use and Duration of Sun Exposure: a Double-Blind, Randomized Trial J Natl Cancer Inst, December 1, 1999; 91(23): 2047 - 2047. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |